Aptose Biosciences Inc  

(Public, NASDAQ:APTO)   Watch this stock  
Find more results for OTC:LRUSF
2.66
-0.03 (-1.12%)
May 27 - Close
NASDAQ real-time data - Disclaimer
Currency in USD
Range 2.59 - 2.71
52 week 1.93 - 6.40
Open 2.71
Vol / Avg. 3,094.00/17,526.00
Mkt cap 32.00M
P/E     -
Div/yield     -
EPS -0.90
Shares 12.11M
Beta 1.43
Inst. own 34%
Aug 2, 2016
Q2 2016 Aptose Biosciences Inc Earnings Release (Estimated) - 4:00PM EDT - Add to calendar
Jun 21, 2016
Aptose Biosciences Inc Annual Shareholders Meeting - 10:00AM EDT - Add to calendar
May 10, 2016
Q1 2016 Aptose Biosciences Inc Earnings Call - Webcast
May 10, 2016
Q1 2016 Aptose Biosciences Inc Earnings Release
May 2, 2016
Aptose Biosciences Inc at Bloom Burton & Co. Healthcare Investor Conference
Mar 29, 2016
Q4 2015 Aptose Biosciences Inc Earnings Call - Webcast
Mar 29, 2016
Q4 2015 Aptose Biosciences Inc Earnings Release
Mar 14, 2016
Aptose Biosciences Inc at ROTH Conference - Webcast
Mar 7, 2016
Aptose Biosciences Inc at Cowen Health Care Conference
More events from DailyFinance »    

Key stats and ratios

Q1 (Mar '16) 2015
Net profit margin - -
Operating margin - -
EBITD margin - -
Return on average assets -108.61% -44.57%
Return on average equity -122.37% -48.90%
Employees 22 -
CDP Score - -

Address

5955 Airport Rd Suite 228
MISSISSAUGA, ON L4V 1R9
Canada
+1-647-4799828 (Phone)
+1-416-7982200 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money

Description

Aptose Biosciences Inc. (Aptose) is a clinical stage biotechnology company. The Company is engaged in development of targeted therapies addressing unmet medical needs in oncology. The Company has product candidates in two classes of anti-cancer therapies: Small molecule program and large molecule program. The Company's group of small molecule compounds includes lead drug APTO-253 in acute myeloid leukemia (AML), myelodysplastic syndromes (MDS) and other hematologic malignancies. APTO-253 is an inducer of the Kruppel-like factor 4 gene (the Klf4 Gene) for patients with advanced hematologic malignancies. Additionally, the Company has a preclinical small molecule program, APTO-500, targeting maternal embryonic leucine zipper kinase (MELK) for the treatment of various cancers. The Company's large molecule program includes a molecule to target specific cell-surface receptors expressed in certain cancers expressing the Interleukin-17E receptor (IL-17ER).

Officers and directors

William Glenn Rice Chairman of the Board, President, Chief Executive Officer
Bio & Compensation  - Reuters
Gregory Kwok Lee Chow Chief Financial Officer, Senior Vice President
Bio & Compensation  - Reuters
Avanish Vellanki Senior Vice President, Chief Business Officer
Bio & Compensation  - Reuters
Denis R. Burger Ph.D. Independent Director
Age: 70
Bio & Compensation  - Reuters
Erich M. Platzer M.D.,Ph.D. Independent Director
Bio & Compensation  - Reuters
Bradley Thompson Independent Director
Bio & Compensation  - Reuters
Mark D. Vincent M.D. Independent Director
Bio & Compensation  - Reuters
Warren Whitehead Independent Director
Bio & Compensation  - Reuters